LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
LENZ Therapeutics (NASDAQ: LENZ) has entered into an exclusive license and commercialization agreement with Lotus Pharmaceutical for LNZ100, a presbyopia treatment eye drop, in Korea and Southeast Asia. The deal includes up to $125 million in upfront and milestone payments, plus double-digit royalties on future sales.
Lotus will have exclusive rights for LNZ100 in Korea, Thailand, Philippines, Vietnam, Malaysia, Brunei, Indonesia, and Singapore. The agreement targets a market of over 100 million people affected by presbyopia in these regions. The FDA has already accepted LENZ's NDA for LNZ100 with a PDUFA date of August 8, 2025.
LENZ Therapeutics (NASDAQ: LENZ) ha stipulato un accordo esclusivo di licenza e commercializzazione con Lotus Pharmaceutical per LNZ100, un collirio per il trattamento della presbiopia, in Corea e nel Sud-est asiatico. L'accordo prevede fino a 125 milioni di dollari tra pagamenti iniziali e milestone, oltre a royalties a doppia cifra sulle vendite future.
Lotus avrà i diritti esclusivi per LNZ100 in Corea, Thailandia, Filippine, Vietnam, Malesia, Brunei, Indonesia e Singapore. L'accordo interessa un mercato di oltre 100 milioni di persone affette da presbiopia in queste regioni. La FDA ha già accettato la NDA di LENZ per LNZ100 con una data PDUFA fissata per l'8 agosto 2025.
LENZ Therapeutics (NASDAQ: LENZ) ha firmado un acuerdo exclusivo de licencia y comercialización con Lotus Pharmaceutical para LNZ100, un colirio para el tratamiento de la presbicia, en Corea y el sudeste asiático. El acuerdo incluye hasta 125 millones de dólares en pagos iniciales y por hitos, además de regalías de dos dígitos sobre ventas futuras.
Lotus tendrá los derechos exclusivos para LNZ100 en Corea, Tailandia, Filipinas, Vietnam, Malasia, Brunéi, Indonesia y Singapur. El acuerdo apunta a un mercado de más de 100 millones de personas afectadas por presbicia en estas regiones. La FDA ya ha aceptado la NDA de LENZ para LNZ100 con una fecha PDUFA del 8 de agosto de 2025.
LENZ Therapeutics (NASDAQ: LENZ)는 한국과 동남아시아에서 노안 치료제인 LNZ100에 대해 Lotus Pharmaceutical과 독점 라이선스 및 상업화 계약을 체결했습니다. 이 계약에는 최대 1억 2,500만 달러의 선급금 및 마일스톤 지급액과 향후 판매에 대한 두 자릿수 로열티가 포함됩니다.
Lotus는 한국, 태국, 필리핀, 베트남, 말레이시아, 브루나이, 인도네시아, 싱가포르에서 LNZ100에 대한 독점 권리를 갖게 됩니다. 이 계약은 이 지역의 1억 명 이상의 노안 환자를 대상으로 합니다. FDA는 이미 LENZ의 LNZ100 NDA를 승인했으며 2025년 8월 8일 PDUFA 날짜가 지정되어 있습니다.
LENZ Therapeutics (NASDAQ : LENZ) a conclu un accord exclusif de licence et de commercialisation avec Lotus Pharmaceutical pour LNZ100, un collyre destiné au traitement de la presbytie, en Corée et en Asie du Sud-Est. L'accord prévoit jusqu'à 125 millions de dollars de paiements initiaux et liés à des jalons, ainsi que des redevances à deux chiffres sur les ventes futures.
Lotus disposera des droits exclusifs pour LNZ100 en Corée, en Thaïlande, aux Philippines, au Vietnam, en Malaisie, à Brunei, en Indonésie et à Singapour. Cet accord cible un marché de plus de 100 millions de personnes atteintes de presbytie dans ces régions. La FDA a déjà accepté la NDA de LENZ pour LNZ100, avec une date PDUFA fixée au 8 août 2025.
LENZ Therapeutics (NASDAQ: LENZ) hat eine exklusive Lizenz- und Vermarktungsvereinbarung mit Lotus Pharmaceutical für LNZ100, ein Augentropfen zur Behandlung von Presbyopie, in Korea und Südostasien abgeschlossen. Der Deal umfasst bis zu 125 Millionen US-Dollar an Voraus- und Meilensteinzahlungen sowie zweistellige Lizenzgebühren auf zukünftige Verkäufe.
Lotus erhält exklusive Rechte für LNZ100 in Korea, Thailand, den Philippinen, Vietnam, Malaysia, Brunei, Indonesien und Singapur. Die Vereinbarung zielt auf einen Markt von über 100 Millionen Menschen mit Presbyopie in diesen Regionen ab. Die FDA hat LENZ’ NDA für LNZ100 bereits akzeptiert, mit einem PDUFA-Datum am 8. August 2025.
- Deal worth up to $125 million in upfront and milestone payments plus double-digit royalties
- Partnership with Lotus, a company with proven track record and double-digit revenue growth exceeding $500M
- Expansion into significant market with over 100 million potential patients
- FDA NDA acceptance already secured with PDUFA date of August 8, 2025
- Product still pending FDA approval
- Pre-commercial stage company with no current revenue from LNZ100
Insights
LENZ secures major $125M licensing deal with Lotus for presbyopia drug LNZ100 in Korea and Southeast Asia markets, significantly expanding global reach.
LENZ Therapeutics has negotiated an impressive licensing agreement with Lotus Pharmaceutical that provides substantial near-term and long-term revenue potential. The deal includes
The agreement strategically targets the Republic of Korea and seven Southeast Asian countries with a combined addressable market of over 100 million presbyopia patients. This partnership leverages Lotus's established commercial infrastructure and proven track record in these regions, where they've demonstrated
Timing is particularly significant as LENZ awaits FDA approval for LNZ100, with a PDUFA date of August 8, 2025. The FDA's decision not to hold an Advisory Committee Meeting suggests a potentially streamlined approval pathway. The licensing agreement diversifies LENZ's revenue streams while allowing them to maintain focus on their US commercialization strategy, a common approach for pre-commercial biopharma companies looking to maximize global market penetration.
This deal represents a milestone in LENZ's stated strategy of partnering with established commercial entities outside the US market. For a pre-commercial company like LENZ, securing substantial non-dilutive capital through licensing improves financial stability during the critical transition to commercialization and reduces dependency on capital markets for additional financing.
Exclusive agreement includes up to
SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced an exclusive license and commercialization agreement for Lotus to commercialize LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast Asia. LENZ Therapeutics is a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia. Lotus is a leading global pharmaceutical company focused on commercializing novel pharmaceuticals to provide patients with better, safer and more accessible medicines.
Under the terms of the licensing and commercialization agreement, LENZ will receive up to
“We are very excited to partner with the team at Lotus to bring LNZ100 to Southeast Asia, given their proven track record for successful global partnerships, robust commercial infrastructure in the region and six consecutive years of double-digit revenue growth, now exceeding USD
Petar Vazharov, Chief Executive Officer of Lotus Pharmaceutical, commented: “We are very pleased to be the trusted partner of LENZ to help bring such a transformative product that will significantly enhance the lives of more than 100 million people in this region who are currently impacted by presbyopia. Our commitment to excellence drives us to diligently pursue the necessary regulatory approvals and eventually leverage our extensive network of channels to ensure seamless access to this life-altering solution. Our dedication to innovation and safety remains unwavering as we continuously strive to provide better and safer pharmaceuticals to the markets that we serve.”
In October 2024, LENZ announced that the FDA accepted the NDA for LNZ100 for the treatment of presbyopia, a condition that impacts an estimated 1.8 billion people globally and 128 million people in the United States. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100, and noted it is not planning to hold an Advisory Committee Meeting to discuss this application.
About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness
| Contacts: | |
| Dan Chevallard | Yu-ying Yang, Associate Director, Corporate Communications |
| LENZ Therapeutics | Lotus Pharmaceutical Co., Ltd. |
| IR@LENZ-Tx.com | investor@lotuspharm.com |
FAQ
What is the value of LENZ Therapeutics' licensing deal with Lotus Pharmaceutical?
Which countries are included in LENZ's LNZ100 commercialization agreement?
When is the FDA PDUFA date for LENZ's LNZ100 presbyopia treatment?
What is the market size for LNZ100 in the licensed territories?
What is LNZ100 and what does it treat?
